Oct 30 (Reuters) - GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.
The drugmaker now expects full-year profit to be about flat compared to last year at constant currency, up from a previous forecast of a fall of 3% to 5%.
Turnover rose 11% to 9.39 billion pounds in the three months ended Sept. 30, a year earlier, said GSK.
Adjusted earnings were 38.6 pence per share.
Analysts on average had expected earnings of 33 pence and sales of 9.02 billion pounds, according to a company-compiled consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus of 15 analysts.
(Reporting by Pushkala Aripaka and Ankur Banerjee in Bengaluru Editing by Tomasz Janowski)